The 5‐HT 2A/2C inverse agonist nelotanserin alleviates L‐DOPA‐induced dyskinesia in the MPTP‐lesioned marmoset
European Journal of Neuroscience · 2024
DOI: 10.1111/ejn.16104 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neuroscience, 2024. Verfasst von Cynthia Kwan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Neurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Dyskinesia, Drug-Induced, Parkinsonian Disorders, Phenylurea Compounds, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Parkinson Canada, Fonds de Recherche du Québec - Santé, Parkinson Québec.
Abstract (Originalsprache)
Nelotanserin is a serotonin 2A and 2C (5‐HT 2A/2C ) inverse agonist that was previously tested in the clinic for rapid‐eye movement sleep behaviour disorder and psychosis in patients with Parkinson's disease (PD) dementia. Its effect on L‐3,4‐dihydroxyphenylalanine (L‐DOPA)‐induced dyskinesia has however not been investigated. As 5‐HT 2A antagonism/inverse agonism is a validated approach to alleviate dyskinesia, we undertook the current study to evaluate the anti‐dyskinetic potential of nelotanserin in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned marmoset. Parkinsonism was induced in six common marmosets ( Callithrix jacchus , three females and three males) that were then chronically treated with L‐DOPA to induce dyskinesia. On experimental days, they were administered L‐DOPA in combination with vehicle or nelotanserin (0.1, 0.3 and 1 mg/kg) subcutaneously, in a randomised fashion. Dyskinesia and parkinsonism were rated post hoc by a blinded observer. In comparison to vehicle, the addition of nelotanserin 0.3 and 1 mg/kg to L‐DOPA diminished peak dose dyskinesia by 47% ( P < 0.05) and 69% ( P < 0.001). Nelotanserin 0.3 and 1 mg/kg also reduced the severity of global dyskinesia, by 40% ( P < 0.01) and 55% ( P < 0.001), when compared to vehicle. Nelotanserin 0.1 mg/kg did not alleviate peak dose or global dyskinesia severity. Nelotanserin had no impact on the anti‐parkinsonian action of L‐DOPA. Our results highlight that nelotanserin may represent an efficacious anti‐dyskinetic drug and provide incremental evidence of the potential benefit of 5‐HT 2A/2C antagonism/inverse agonism for drug‐induced dyskinesia in PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), Montreal, Quebec, Canada.
- Département de Pharmacologie et Physiologie, Université de Montréal, Montreal, Quebec, Canada.
- Comparative Medicine & Animal Resource Centre, McGill University, Montreal, Quebec, Canada.
- Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
- Movement Disorder Clinic, Division of Neurology, Department of Neurosciences, McGill University Health Centre, Montreal, QC, Canada.
ORCID-Profile: Adjia Hamadjida, Philippe Huot
Förderung
- Parkinson Canada
- Fonds de Recherche du Québec - Santé
- Parkinson Québec
- Weston Brain Institute
- The Michael J. Fox Foundation for Parkinson's Research
- Natural Sciences and Engineering Research Council of Canada
- Social Sciences and Humanities Research Council of Canada
- Healthy Brains, Healthy Lives
Zitieren
APA
Kwan, C., Frouni, I., Bédard, D., Hamadjida, A., Nuara, S. G., Gourdon, J. C., & Huot, P. (2024). The 5‐HT 2A/2C inverse agonist nelotanserin alleviates L‐DOPA‐induced dyskinesia in the MPTP‐lesioned marmoset. European Journal of Neuroscience. https://doi.org/10.1111/ejn.16104
Vancouver
Kwan C, Frouni I, Bédard D, Hamadjida A, Nuara SG, Gourdon JC, et al. The 5‐HT 2A/2C inverse agonist nelotanserin alleviates L‐DOPA‐induced dyskinesia in the MPTP‐lesioned marmoset. European Journal of Neuroscience. 2024. doi:10.1111/ejn.16104
BibTeX
@article{Kwan2024,
author = {Kwan, Cynthia and Frouni, Imane and Bédard, Dominique and Hamadjida, Adjia and Nuara, Stephen G and Gourdon, Jim C and Huot, Philippe},
title = {The 5‐HT 2A/2C inverse agonist nelotanserin alleviates L‐DOPA‐induced dyskinesia in the MPTP‐lesioned marmoset},
journal = {European Journal of Neuroscience},
year = {2024},
doi = {10.1111/ejn.16104}
}
EUVIMED